ArticleNPJ Parkinson's disease2024
Disease progression strikingly differs in research and real-world Parkinson's populations.
Article in NPJ Parkinson's disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Medication Knowledge of Patients with Parkinson's Disease: Strengths and Gaps.Movement disorders clinical practice · 2026Article
- Multi-locus genetic dosage shapes cognitive disease progression in Parkinson's patients: 15-year meta-analysis of 24 cohorts.NPJ Parkinson's disease · 2026Article
- Anxiety is associated with increased risk of suicidality in Parkinson's disease.Journal of Parkinson's disease · 2026Article
- Accessible assessment of motor and cognitive symptoms in Parkinson's disease: integrating large datasets, machine-learning, and videoconferencing.NPJ digital medicine · 2026Article
- Propensity-matched multicenter comparison of Parkinson's disease outcomes with and without deep brain stimulation.NPJ Parkinson's disease · 2026Article
- Nationwide analysis of real-world access to and use of device-aided therapies in Parkinson's disease: insights from the French National Healthcare Data System (2015-2021).BMJ neurology open · 2026Article
- Differences in Parkinson's Disease Populations: Teaching Hospitals Versus Other Settings and Implications for Clinical Trials.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Parkinson's Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation.Cells · 2025Review
- Cerebrospinal Fluid Phosphorylated Alpha-Synuclein in Newly Diagnosed Parkinson's Disease.European journal of neurology · 2025Article
- Dementia risk prediction in early Parkinson's disease: Validation and genetic integration of the Montreal Parkinson risk of dementia scale (MoPaRDS).Journal of Parkinson's disease · 2025Article
- Personalized medication recommendations for Parkinson's disease patients using gated recurrent units and SHAP interpretability.Scientific reports · 2025Article
- Review
- Synthetic data distillation enables the extraction of clinical information at scale.NPJ digital medicine · 2025Article
- Prasinezumab: A Bayesian Perspective on Its Efficacy.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Validation of Parkinson's Disease Ascertainment in the Veterans Administration Electronic Medical Record.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- A lightweight cerebrospinal fluid biomarker-based model for first-diagnosis prediction of Parkinson's disease: model development, external validation, and local deployment.Frontiers in aging neuroscience · 2025Article
- Long-Term Real-World Experience with Safinamide in Patients with Parkinson's Disease.Brain sciences · 2024Article
- Serum neurofilament light at diagnosis: a prognostic indicator for accelerated disease progression in Parkinson's Disease.NPJ Parkinson's disease · 2024Article
Corrections and comments
- Update of
Authors and funding
13 authors at 5 institutions in 3 countries.
Funding
Abstract
Characterization of Parkinson's disease (PD) progression using real-world evidence could guide clinical trial design and identify subpopulations. Efforts to curate research populations, the increasing availability of real-world data, and advances in natural language processing, particularly large language models, allow for a more granular comparison of populations than previously possible. This study includes two research populations and two real-world data-derived (RWD) populations. The research populations are the Harvard Biomarkers Study (HBS, N = 935), a longitudinal biomarkers cohort study with in-person structured study visits; and Fox Insights (N = 36,660), an online self-survey-based research study of the Michael J. Fox Foundation. Real-world cohorts are the Optum Integrated Claims-electronic health records (N = 157,475), representing wide-scale linked medical and claims data and de-identified data from Mass General Brigham (MGB, N = 22,949), an academic hospital system. Structured, de-identified electronic health records data at MGB are supplemented using a manually validated natural language processing with a large language model to extract measurements of PD progression. Motor and cognitive progression scores change more rapidly in MGB than HBS (median survival until H&Y 3: 5.6 years vs. >10, p < 0.001; mini-mental state exam median decline 0.28 vs. 0.11, p < 0.001; and clinically recognized cognitive decline, p = 0.001). In real-world populations, patients are diagnosed more than eleven years later (RWD mean of 72.2 vs. research mean of 60.4, p < 0.001). After diagnosis, in real-world cohorts, treatment with PD medications has initiated an average of 2.3 years later (95% CI: [2.1-2.4]; p < 0.001). This study provides a detailed characterization of Parkinson's progression in diverse populations. It delineates systemic divergences in the patient populations enrolled in research settings vs. patients in the real-world. These divergences are likely due to a combination of selection bias and real population differences, but exact attribution of the causes is challenging. This study emphasizes a need to utilize multiple data sources and to diligently consider potential biases when planning, choosing data sources, and performing downstream tasks and analyses.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.